---
title: "OBiO Tech: Plans to repurchase shares for 50 million to 100 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/229004717.md"
description: "OBiO Tech announced that the company plans to repurchase shares with funds ranging from 50 million to 100 million yuan, with a repurchase price not exceeding 7 yuan per share. The repurchased shares will be used entirely for equity incentives or employee stock ownership plans, as well as to maintain the company's value and shareholder rights. The expected number of repurchased shares is between 7.1429 million and 14.2857 million shares, accounting for 1.10%-2.20% of the company's total share capital. The repurchase period is within 3 months from the date of approval by the board of directors, with funding sourced from the company's own funds and a special loan for stock repurchase"
datetime: "2025-02-20T10:28:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/229004717.md)
  - [en](https://longbridge.com/en/news/229004717.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/229004717.md)
generator: "portal-rs"
---

# OBiO Tech: Plans to repurchase shares for 50 million to 100 million yuan

OBiO Tech announced that the company plans to repurchase shares with funds ranging from 50 million to 100 million yuan, with a repurchase price not exceeding 7 yuan per share. The repurchased shares will be used entirely for equity incentives or employee stock ownership plans, as well as to maintain the company's value and shareholder rights. The estimated number of repurchased shares is between 7.1429 million and 14.2857 million shares, accounting for 1.10% to 2.20% of the company's total share capital. The repurchase period is within 3 months from the date of approval by the board of directors, with funding sourced from the company's own funds and a special loan for stock repurchase

### Related Stocks

- [688238.CN](https://longbridge.com/en/quote/688238.CN.md)

## Related News & Research

- [Hollywood summer box office hits pre-pandemic stride as women, younger audiences return to theaters](https://longbridge.com/en/news/298021676.md)
- [Khan demands Burnham block Heathrow expansion over net zero](https://longbridge.com/en/news/297836820.md)
- [Biohit says scientific review backs serum biomarker triage to target endoscopy for gastric cancer risk](https://longbridge.com/en/news/297887371.md)
- [NeuroGT Announces FDA Clearance of Investigational New Drug Application for NGT-104, an AAV9 Gene Replacement Product for MPS IIIB](https://longbridge.com/en/news/297947685.md)
- [Egetis says new Emcitate clinical data from Triac Trial II, ReTRIACt to be presented at September congresses](https://longbridge.com/en/news/297996002.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**